Drugs / Adipose Derived MSCs (ADMSCs)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02135380 | Aug 2014 → Aug 2015 | idiopathic pulmonary fibrosis | Kasiak Research Pvt. Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adipose Derived MSCs (ADMSCs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02135380 ↗ |
| Known as | Mesenchymal stem cells (MSC) | “Study arm B subjects will receive total 3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each.” NCT02135380 ↗ |
| Modality | Cell therapy | “Human mesenchymal stem cells (MSCs) are present as a rare population of cells in adipose tissue” NCT02135380 ↗ |
| Route | Intravenous | “Study arm B subjects will receive total 3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each.” NCT02135380 ↗ |